miR-210 as a marker of chronic hypoxia, but not a therapeutic target in prostate cancer

miR-210 could be an interesting marker of chronic hypoxia irrespective of the androgen dependency and should, therefore, be tested as a prognostic marker in high risk prostate cancer patients.